



*File*

CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE WITH SUFFICIENT POSTAGE AS FIRST-CLASS MAIL IN AN ENVELOPE ADDRESSED TO:

COMMISSIONER FOR PATENTS, P.O. BOX 1450  
ALEXANDRIA, VA 22313-1450 ON MAY 25, 2007.

*Trudy S. Halonen*

Signature of person depositing this document

*5-25-2007*

DATE

Attorney Docket No. P32976

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Daines *et al.*

May 25, 2007

Serial No.: 10/502,233

Group Art Unit No.: 1625

Filed: July 22, 2004

Examiner: Z. Davis

For: AMINOPIPERIDINE DERIVATIVES

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Supplemental Information Disclosure Statement Under 37 C.F.R. §1.97(c)(2)

The attached list of citations is being submitted under the provisions of 37 C.F.R. §1.56 and §1.97 in order to comply with the duty of disclosure. Their inclusion herein, however, should not be construed as an admission that any particular cited reference is effective prior art or that it discloses or renders obvious any aspect of the claimed invention.

The documents cited herein are listed on the enclosed PTO Form 1449. A copy of each cited document is enclosed, except U.S. Patent documents, and those references which are already part of the filewrapper. This statement is being filed under the provisions of 37 C.F.R. §1.97(c)(2).

Some of the documents listed in the attached form PTO-1449 are not in the English language. Listed below are English language family members for the noted non-English publications:

Non-English language document	English language family member
WO01/25227	US 6,403,610, see also EP1218370B1 English language claims
WO02/040474	US 6,603,005; US 6,903,217
WO02/072572	US 6,602,884; US 6,815,547
WO04/024712	US 2004/0087619A1

Serial No.: 10/502,233

WO04/024713	US 6,841,562
WO04/035569A2	US 2006/0040949A1
BE772190A1	GB1345872
EP0374095A2	CA2004986A1
EP0532456A1, B1	US 5,310,743; US 5,541,195; US 5,646,144; see also EP0532456B1 claims
EP0541486A1	US 5,264,431

USAN 10/868,315, 10/199,933 and 10/937,468 are unpublished US patent applications, which will not publish prior to US grant. The Examiner is respectfully requested to consider these applications.


Authorization is given to charge the fee due under 37 C.F.R. §1.17(p), and any fees under 37 C.F.R. §1.16 or §1.17 which may be required by this paper, or credit any overpayment, to Deposit Account 19-2570.

Respectfully submitted,



Loretta J. Sauermelech  
Attorney for Applicants

GLAXOSMITHKLINE  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, PA 19406-0939  
Telephone: (610) 270-6854  
Facsimile: (610) 270-5073  
n:\Loretta\Applications\IP32976\SupplDS a.doc

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. P32976	SERIAL NO. 10/502,233
 <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p>(Use several sheets if necessary)</p>		APPLICANT Daines <i>et al.</i>	
		FILING DATE July 22, 2004	GROUP 1625

## U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	5,264,431	11/23/93	Wacker <i>et al.</i>	514	211	11/6/92
	5,310,743	5/10/94	Schilling, <i>et al.</i>	514	311	8/11/92
	5,541,195	7/30/96	Schilling, <i>et al.</i>	514	311	4/4/94
	5,646,144	7/8/97	Schilling, <i>et al.</i>	514	241	6/7/95
	6,403,610B1	6/11/02	Malleron <i>et al.</i>	514	314	9/18/00
	6,602,882B1	8/5/03	Davies <i>et al.</i>	514	300	PCT 10/11/99
	6,602,884B2	8/5/03	Bacque <i>et al.</i>	514	314	3/13/02
	6,603,005B2	8/5/03	Baque <i>et al.</i>	546	176	11/14/01
	6,803,369B1	10/12/04	Erskine <i>et al.</i>	514	253.06	7/25/01
	6,815,547B2	11/9/04	Bacque <i>et al.</i>	546	174	3/14/03
	6,841,562B2	1/11/05	Bacque <i>et al.</i>	514	314	9/10/03
	6,903,217B2	6/7/05	Bacque <i>et al.</i>	546	180	6/27/03
	6,911,442B1	6/28/05	Davies <i>et al.</i>	514	230.5	PCT 6/13/00
	6,962,917		Davies <i>et al.</i>	514	264.1	PCT 7/25/01
	6,989,447B2	1/24/06	Markwell <i>et al.</i>	546	152	11/24/03
	7,001,913B1	2/21/06	Davies <i>et al.</i>	514	300	PCT 7/17/02
	7,141,564	11/28/06	Brooks <i>et al.</i>	514	248	PCT 5/24/02
	7,186,730	3/6/07	Dartois <i>et al.</i>	514	266.22	PCT 5/24/02
	7,205,408	4/17/07	Davies <i>et al.</i>	514	243	PCT 1/22/02
	2003-0203917A1 (10/441,435)	10/30/03	Erskine <i>et al.</i>	514	253.06	5/20/03
	2004-0087619A1 (10/659,164)	5/6/04	Bacque <i>et al.</i>	514	314	9/10/03
	2005-0085494A1 (10/502,234)	04/21/2005	Daines <i>et al.</i>	514	266.22	PCT 1/27/03

		2006-0014749A1 (11/219,148)	1/19/06	Davies et al.	514	249	9/2/05
		2006-0040925A1 (10/522,058)	2/23/06	Davies et al.	514	222.8	PCT 7/23/03
		2006-0040949A1 (10/529,986)	2/23/06	Surviet et al.	514	253.04	PCT 10/9/03
		2006-0041123A1 (10/538,931)	2/23/06	Axten et al.	544	48	PCT 12/17/03
		2006-0058287A1 (10/518,655)	3/16/06	Axten et al.	514	224.2	PCT 6/25/03
		2006-0116512A1 (10/537,034)	6/1/06	Axten et al.	544	048	PCT 12/3/03
		2006-0166977A1 (10/533,502)	7/27/06	Axten et al.	514	224.2	PCT 11/4/03
		2006-0189604A1 (10/518,653)	8/24/06	Axten et al.	514	224.2	PCT 6/25/03
		2007-0004710A1 (10/533,501)	1/4/07	Axten et al.	514	224.2	PCT 11/4/03
		USAN 11/604,045		Brooks et al.			11/22/06

# FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Sub-class	Translation	
							Yes	No
		WO 95/09853	4/13/95	WIPO				
		WO 96/15128	5/23/96	WIPO				
		WO 96/38144	12/5/96	WIPO				
		WO 97/03069	01/30/97	WIPO				
		WO 97/17957	5/22/97	WIPO				
		WO 97/45119	12/4/97	WIPO				
		WO 98/02438	01/22/98	WIPO				
		WO 99/37635	7/29/99	WIPO				
		WO 00/21948	4/20/00	WIPO				
		WO 00/21952	4/20/00	WIPO				
		WO 00/43383	7/27/00	WIPO				
		WO 00/78748A1	12/28/00	WIPO				
		WO 01/07433A2	2/1/01	WIPO				
		WO 01/25227A2	4/12/01	WIPO			PCT Abstract, family member, EP claims	

	WO 01/087839A1 Rev.	11/22/01	WIPO				
	WO 02/24684A1	3/28/02	WIPO				
	WO 02/40474A2	5/23/02	WIPO			PCT Abstract, family members	
	WO 02/50040A1	6/27/02	WIPO				
	WO 02/50061A1	6/27/02	WIPO				
	WO 02/072572A1	9/19/02	WIPO			PCT Abstract, family members	
	WO 02/96907A1	12/5/02	WIPO				
	WO 03/010138A2	2/6/03	WIPO				
	WO 03/064431A2	8/7/03	WIPO				
	WO 03/087098	10/23/03	WIPO				
	WO 04/002490A2	1/8/04	WIPO				
	WO 04/002992A1	1/8/04	WIPO				
	WO 04/014361A1 Corr.	2/19/04	WIPO				
	WO 04/024712A1	3/25/04	WIPO			PCT Abstract, family member	
	WO 04/024713A1	3/25/04	WIPO			PCT Abstract, family member	
	WO 04/035569A2	4/29/04	WIPO			PCT Abstract, family member	
	WO 04/041210A2	5/21/04	WIPO				
	WO 04/050036A2	6/17/04	WIPO				
	WO 04/058144A2	7/15/04	WIPO				

	WO 04/096982A2	11/11/04	WIPO				
	BE772190A1	1/17/72	Belgium			Family member	
	CA 2,004,986A1	6/12/90	Canada				
	EP 0238868A2	9/30/87	EPO				
	EP 0304493A1	3/1/89	EPO				
	EP 0374095A2	6/20/90	EPO			Family member, abstract	
	EP 0532456A1	3/17/93	EPO			Family members, B1 claims	
	EP 0532456B1	3/29/95	EPO			claims	
	EP 0541486A1	5/12/93	EPO			Family member	
	EP 0823429A1	2/11/98	EPO				
	EP 1218370B1	12/8/04	EPO			FR2798656 Abstract, claims	
	GB 1345872	2/6/74	Great Britain				
	GB 1537867	1/10/79	Great Britain				
	JP 1995179407A	7/18/95	Japan			Machine translation	

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER		DATE CONSIDERED	
-EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

**CO-PENDING UNPUBLISHED US PATENT APPLICATIONS**

Examiner Initial	Attorney Docket No.	USAN	Inventors	Filing Date	Title	PCT publication
	P51113C	10/868351 (cont of 09/912610, abandoned)	Erskine et al.	6/15/04	Compounds and Methods for the Treatment of Disease	-
	P51113-1	10/199933, CIP of 09/912610	Erskine et al.	7/19/02	Compounds and Methods for the Treatment of Disease	-
	P51113-2	10/937468, CIP of 09/912610	Erskine et al.	9/9/04	Compounds and Methods for the Treatment of Disease	-
EXAMINER				DATE CONSIDERED		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.						

n/loretta/applications/P3s/P32976/supp 1449a.doc